Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

Because of the molecular structure and low molecular weight (148 g/mol), resorption of the test item via the gastrointestinal tract is considered to be likely.

In the acute toxicity study with oral administration (Heusener & von Eberstein, 2000), the following signs of toxicity were observed: locomotor disturbance, dyspnea, motor excitation and death. Additionally, in the subacute toxicity study with rats at doses of 50, 150 and 450 mg/kg showed increased liver weights and hepatocellular hypertrophy as well as alterations of clinical-chemistry parameters at 150 and 450 mg/kg (Braun et al., 2004). Hence, there is sufficient evidence for resorption of the test item in the gastrointestinal tract.

Because systemic effects were observed in the subacute toxicity study, distribution of the substance throughout the body and systemic availability after oral administration can be assumed.

Information on the excretion of the substance is not available. But because the effects observed in the subacute toxicity study were mainly reversible within the 14-day treatment free recovery period, it can be concluded that the substance is readily eliminated from the body. Due to the molecular structure and low molecular weight of the substance, excretion via the kidneys is considered to be the main route of elimination.

References:

Braun WH, Flade D, Waldvogel A (2004) Art. 270965: 28-day oral toxicity (gavage) study in the wistar rat. RCC study number 854324, unpublished report

Heusener A, von Eberstein M (2000) Art. 270965 - Acute toxicity study in rats after oral administration. Merck KGaA study number T14759, unpublished report

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential

Additional information